With its focus on drug delivery systems, i.e. biodegradable drug delivery systems, this pharmaceutical company provides patients and partners with access to high-quality medicines and cost-effective therapies. Based on its technology platform, AMW builds on a growing pipeline of own product candidates and those developed with partners. The company has two approved products, goserelin and leuprorelin implants which are distributed worldwide by local and global pharmaceutical partners. Leuprorelin is marketed in Germany under the name Leugon® by the wholly- owned AMW subsidiary Endomedica GmbH. To support pharmaceutical and biotech partners in the development and manufacture of their products and life-cycle solutions, AMW leverages its leading expertise in formulation development. AMW GmbH is based in Warngau in the greater Munich area.
